Stem cell therapy for preventing neonatal diseases in the 21st century: Current understanding and challenges
- 14 May 2019
- journal article
- review article
- Published by Springer Nature in Pediatric Research
- Vol. 87 (2) , 265-276
Abstract
Diseases of the preterm newborn such as bronchopulmonary dysplasia, necrotizing enterocolitis, cerebral palsy, and hypoxic-ischemic encephalopathy continue to be major causes of infant mortality and long-term morbidity. Effective therapies for the prevention or treatment for these conditions are still lacking as recent clinical trials have shown modest or no benefit. Stem cell therapy is rapidly emerging as a novel therapeutic tool for several neonatal diseases with encouraging pre-clinical results that hold promise for clinical translation. However, there are a number of unanswered questions and facets to the development of stem cell therapy as a clinical intervention. There is much work to be done to fully elucidate the mechanisms by which stem cell therapy is effective (e.g., anti-inflammatory versus pro-angiogenic), identifying important paracrine mediators, and determining the timing and type of therapy (e.g., cellular versus secretomes), as well as patient characteristics that are ideal. Importantly, the interaction between stem cell therapy and current, standard-of-care interventions is nearly completely unknown. In this review, we will focus predominantly on the use of mesenchymal stromal cells for neonatal diseases, highlighting the promises and challenges in clinical translation towards preventing neonatal diseases in the 21st century.Keywords
This publication has 141 references indexed in Scilit:
- Concise Review: Mesenchymal Stem Cells for Acute Lung Injury: Role of Paracrine Soluble FactorsStem Cells, 2011
- Necrotizing EnterocolitisNew England Journal of Medicine, 2011
- Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs)Journal of Cellular and Molecular Medicine, 2010
- Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory propertiesProceedings of the National Academy of Sciences, 2010
- Bone Marrow Stromal Cells Attenuate Lung Injury in a Murine Model of Neonatal Chronic Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Airway Delivery of Mesenchymal Stem Cells Prevents Arrested Alveolar Growth in Neonatal Lung Injury in RatsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lungProceedings of the National Academy of Sciences, 2009
- Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 productionNature Medicine, 2008
- Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injuryProceedings of the National Academy of Sciences, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006